Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Back to future again

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on May 17, 2022 10:55pm

88 Views

Post# 34691259

RE:RE:RE:RE:RE:RE:RE:Back to future again

The real problem is not opacity on their part. That I can understand. The real problem is the enormous delay in finishing phase Ia. It took them 6-8 months more than what they were saying it would last summer. So you add these 6-8 months, and it makes for a very long time under radio silence. And on the reasons for the huge delay they are also silent. Without undue delay, we would know by now what the situation is with TH1902. Instead of that, it will have taken around 16-18 months to hopefully know something real about this trial. They failed at execution, not communication.